Daratumumab (PBS)

• UNSPSC Description:

  Daratumumab (PBS) (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab (PBS) has anti-multiple myeloma (MM) effect. Daratumumab (PBS) impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition[1][2].

• Target Antigen:

  ADC Antibody; CD38

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Antibody-drug Conjugate/ADC Related;Immunology/Inflammation

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/daratumumab-pbs.html

• Purity:

  95.0

• Solubility:

  10 mM in DMSO

• Smiles:

  [Daratumumab (PBS)]

• References & Citations:

  [1]Ghose J, Viola D, et al. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology. 2018;7(10):e1486948. Published 2018 Jul 23.|[2]de Weers M, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840-1848.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Clinical Information:

  Phase 4

• CAS Number:

  945721-28-8